XML 120 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Note 5 - Balance Sheet Components
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]
NOTE 
5.
  Balance Sheet Components
 
(a)
    
Cash and Cash Equivalents
 
Cash and cash equivalents comprises the following:
 
   
December 31, 2019
   
December 31, 2018
 
   
(in thousands)
 
Cash at banks
  $
13,511
    $
11,441
 
Restricted cash
   
     
50
 
Money market funds
   
15
     
15
 
Cash and cash equivalents
  $
13,526
    $
11,506
 
 
(b)
    
Accounts Receivable
 
Accounts receivable comprises the following:
 
   
December 31, 2019
   
December 31, 2018
 
   
(in thousands)
 
Royalties receivable
  $
3,438
    $
1,776
 
Customer service contracts – billed
   
181
     
 
Government contract – billed
   
     
20
 
Accounts receivable
  $
3,619
    $
1,796
 
 
(c)
    
Property and Equipment, Net
 
Property and equipment, net consists of the following:
 
   
December 31, 2019
   
December 31, 2018
 
   
(in thousands)
 
Laboratory equipment
  $
537
    $
2,076
 
Office and computer equipment
   
132
     
227
 
Leasehold improvements
   
     
333
 
Total property and equipment
   
669
     
2,636
 
Less: accumulated depreciation
   
(459
)    
(1,570
)
Property and equipment, net
  $
210
    $
1,066
 
 
Depreciation expense was
$504,000
and
$476,000
for the years ended
December 31, 2019
and
2018
, respectively. Property and equipment and leasehold improvements at
one
of the Company’s leased premises in California that were used in the Company’s manufacturing operations (see Note
14
) were assessed as impaired as of
December 31, 2019,
and accordingly an impairment charge of
$1,152,000
 was recorded as a component of restructuring costs within operating expenses. Leasehold improvements and furniture at the Company’s leased premises in Georgia, which has been subleased, commencing in
November 2018,
for less than the rental that the Company is obligated to pay (see Note
8
), were assessed as impaired as of
September 30, 2018,
and accordingly an impairment charge of
$106,000
was recorded as a component of costs of exit from leased premises within operating expenses.
 
(d)
     Right-of-Use
 Assets, Net
 
Right-of-use assets consist of the following:
 
   
December 31, 2019
 
   
(in thousands)
 
Facilities
  $
1,985
 
Office equipment
   
5
 
Right-of-use assets, net
  $
1,990
 
 
The right of use of
one
of the Company’s leased premises in California that were used in the Company’s manufacturing operations (see Note
14
) was assessed as impaired as of
December 31, 2019,
and accordingly an impairment charge of
$120,000
 was recorded as a component of restructuring costs within operating expenses.
 
(e)
    
Intangible Assets, Net
 
Intangible assets comprise developed technology, intellectual property and, until it was considered fully impaired, in-process research and development. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from
1.3
to
11.75
years for developed technology and
20
 years for intellectual property. As of
December 31, 2019,
developed technology and intellectual property had remaining lives of
9.9
and
8.0
years, respectively. Intangible assets consist of the following:
 
   
December 31, 2019
   
December 31, 2018
 
   
(in thousands)
 
Purchased technology
  $
22,100
    $
22,100
 
Intellectual property
   
80
     
80
 
Total cost
   
22,180
     
22,180
 
Less accumulated amortization
   
(5,087
)    
(2,767
)
Intangible assets, net
  $
17,093
    $
19,413
 
 
Intangible asset amortization expense was
$2,320,000
and
$2,727,000
for the years ended
December 31, 2019
and
2018
, respectively. Following the results of Phase
2
trials in
June 2018,
the in-process research and development was assessed as fully impaired in the
three
months ended
June 
30,
2018,
with the
$1.6
million acquired in the Merger (see Note
3
) being charged to operating expenses.
 
As of
December 31, 2019
, the estimated future amortization expense by year is as follows (in thousands):
 
Year Ending December 31,
 
Amount
 
2020
  $
1,732
 
2021
   
1,732
 
2022
   
1,732
 
2023
   
1,731
 
2024
   
1,732
 
Thereafter
   
8,434
 
Total
  $
17,093
 
 
(f)
    
Other Accrued Liabilities
 
Other accrued liabilities consist of the following:
 
   
December 31, 2019
   
December 31, 2018
 
   
(in thousands)
 
Accrued compensation
  $
903
    $
632
 
Accrued clinical and manufacturing expenses
   
3,228
     
75
 
Accrued professional and consulting services
   
2
     
166
 
Reserve for return of royalties
   
178
     
339
 
Deferred rent and lease loss accrual, current portion
   
     
111
 
Other
   
254
     
195
 
Total
  $
4,565
    $
1,518